A new pill, tavapadon, has shown potential in easing Parkinson’s symptoms while limiting side effects. In patients taking at ...

For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time vs placebo.

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

This milestone is a testament to King’s College Hospital Dubai’s unwavering dedication to offering groundbreaking, patient-centered care.

As one of the leading facilities for advanced neurological and Parkinson’s care in the region, King’s College Hospital Dubai ...

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not ...

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

Two early-phase clinical trials demonstrate the safety and potential clinical utility of stem cell therapies to ease motor ...

The first choice of treatment is the administration of levodopa, a precursor to dopamine that is readily transported from the bloodstream into the brain. However, as Parkinson’s disease ...

Parkinson’s disease primarily affects dopamine neurons in the substantia nigra, a region of the brain crucial for movement and emotional regulation. As these neurons die, the brain’s dopamine levels ...

BioVie (BIVI) announced that patient enrollment is now open for the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of ...